ABN Amro Investment Solutions Makes New Investment in Waters Corporation $WAT

ABN Amro Investment Solutions acquired a new stake in shares of Waters Corporation (NYSE:WAT) during the 4th quarter, Holdings Channel reports. The fund acquired 1,776 shares of the medical instruments supplier’s stock, valued at approximately $675,000.

Other large investors also recently modified their holdings of the company. Brighton Jones LLC boosted its position in shares of Waters by 112.9% during the fourth quarter. Brighton Jones LLC now owns 1,269 shares of the medical instruments supplier’s stock worth $471,000 after acquiring an additional 673 shares during the last quarter. Integrated Wealth Concepts LLC increased its stake in Waters by 2.9% in the 1st quarter. Integrated Wealth Concepts LLC now owns 1,048 shares of the medical instruments supplier’s stock worth $386,000 after buying an additional 30 shares during the period. Goldman Sachs Group Inc. increased its stake in Waters by 3.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 200,051 shares of the medical instruments supplier’s stock worth $73,733,000 after buying an additional 6,976 shares during the period. Empowered Funds LLC increased its stake in Waters by 16.6% in the 1st quarter. Empowered Funds LLC now owns 1,126 shares of the medical instruments supplier’s stock worth $415,000 after buying an additional 160 shares during the period. Finally, Sivia Capital Partners LLC purchased a new position in Waters in the 2nd quarter worth about $232,000. Hedge funds and other institutional investors own 94.01% of the company’s stock.

Insider Buying and Selling at Waters

In other news, Director Wei Jiang purchased 500 shares of the stock in a transaction dated Monday, March 16th. The shares were acquired at an average cost of $289.46 per share, for a total transaction of $144,730.00. Following the acquisition, the director owned 3,441 shares of the company’s stock, valued at approximately $996,031.86. This represents a 17.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.31% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on WAT shares. Barclays raised their price target on shares of Waters from $400.00 to $425.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Morgan Stanley reduced their price target on shares of Waters from $423.00 to $350.00 and set an “equal weight” rating on the stock in a research note on Sunday, February 22nd. Wells Fargo & Company raised their price target on shares of Waters from $355.00 to $370.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 14th. JPMorgan Chase & Co. raised their target price on shares of Waters from $330.00 to $345.00 and gave the company a “neutral” rating in a research report on Wednesday, May 6th. Finally, Bank of America cut their target price on shares of Waters from $410.00 to $350.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 10th. Three investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, Waters has an average rating of “Moderate Buy” and an average price target of $396.00.

Waters Trading Up 0.1%

NYSE WAT opened at $342.83 on Monday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.13 and a current ratio of 1.79. The company has a market capitalization of $33.66 billion, a price-to-earnings ratio of 43.56, a price-to-earnings-growth ratio of 2.16 and a beta of 1.14. The company’s 50-day simple moving average is $317.26 and its two-hundred day simple moving average is $351.59. Waters Corporation has a one year low of $275.05 and a one year high of $414.15.

Waters (NYSE:WAT) last posted its earnings results on Tuesday, May 5th. The medical instruments supplier reported $2.70 EPS for the quarter, beating analysts’ consensus estimates of $2.31 by $0.39. The business had revenue of $1.27 billion for the quarter, compared to the consensus estimate of $1.20 billion. Waters had a net margin of 11.91% and a return on equity of 15.60%. The company’s revenue for the quarter was up 91.4% on a year-over-year basis. During the same quarter last year, the firm posted $2.25 EPS. Waters has set its Q2 2026 guidance at 2.950-3.050 EPS and its FY 2026 guidance at 14.400-14.600 EPS. Equities analysts forecast that Waters Corporation will post 14.5 EPS for the current fiscal year.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.